Prostate Cancer - Results from #120

Positive Guidance from the U.S. FDA on 64Cu-SAR-bisPSMA Phase III Trial in Patients with Recurrence of Prostate Cancer October 15, 2024

Prospective, Randomized Controlled Pivotal Trial of Biodegradable Balloon Rectal Spacer for Prostate Radiation Therapy October 15, 2024

Five-Year Prostate-Specific Membrane Antigen Positron Emission Tomography-Based Outcomes of Spot-Scanning Proton Radiation Therapy for Localized Prostate Cancer: A Single Institution Experience October 15, 2024

Prognostic model for second progression-free survival and overall survival in patients with high-risk metastatic hormone-sensitive prostate cancer treated with abiraterone acetate and androgen deprivation therapy. October 15, 2024

Perturbations in the blood metabolome up to a decade before prostate cancer diagnosis in 4387 matched case-control sets from the European Prospective Investigation into Cancer and Nutrition. October 15, 2024

"I Just Had to Do What I Had to Do": Characterizing Direct and Indirect Prostate Cancer Treatment Costs for Black Survivors and Their Caregivers. October 15, 2024

Impact of Gene Expression Classifier Testing on Adjuvant Treatment Following Radical Prostatectomy: The G-MINOR Prospective Randomized Cluster-crossover Trial. October 15, 2024

Size and SUVmax define the contribution of nodal metastases to PSA in oligorecurrent prostate cancer. October 15, 2024

Systemic immune-inflammation index is associated with high risk for prostate cancer among the U.S. elderly: Evidence from NHANES 2001-2010. October 15, 2024

The prognostic role of pan-immune inflammation value in patients with metastatic castration resistance prostate cancer treated with Lutetium-177 (177Lu)-PSMA-617. October 15, 2024

PSMA PET/CT for treatment response evaluation at predefined time points is superior to PSA response for predicting survival in metastatic castration-resistant prostate cancer patients October 14, 2024

Early Prostate-Specific Antigen Response by 6 Months Is Predictive of Treatment Effect in Metastatic Hormone Sensitive Prostate Cancer: An Exploratory Analysis of the TITAN Trial October 14, 2024

Safety and clinical activity of BMS-986365 (CC-94676), a dual androgen receptor ligand-directed degrader and antagonist, in heavily pretreated patients with metastatic castration-resistant prostate cancer. October 14, 2024

Testing home-based exercise strategies in underserved minority cancer patients undergoing chemotherapy (THRIVE) trial: a study protocol. October 14, 2024

Nivolumab in patients with metastatic castration-resistant prostate cancer with and without DNA repair defects. October 14, 2024

Radiotherapy and theranostics: a Lancet Oncology Commission. October 14, 2024

Stimulating Soluble Guanylyl Cyclase with the Clinical Agonist Riociguat Restrains the Development and Progression of Castration-Resistant Prostate Cancer. October 14, 2024

Post-Treatment surveillance intensity and overall survival in prostate cancer survivors (AFT-30). October 14, 2024

Loss of PI5P4Kα slows the progression of a Pten mutant basal cell model of prostate cancer. October 14, 2024

Management of Patients with Advanced Prostate Cancer. Report from the 2024 Advanced Prostate Cancer Consensus Conference (APCCC). October 14, 2024

Page 7 of 1437